For patients exhibiting clinically clear signs of hyperphagia — such as chronic hunger, frequent snacking, and heightened food-cue reactivity — GLP-1 medications may offer significant relief. However, in addition to pharmacotherapy, a comprehensive treatment approach may be beneficial for these patients.

In the context of hyperphagia — defined as an abnormally increased or excessive appetite — Prader-Willi Syndrome often comes to mind.¹ However, hyperphagia can also arise from living in an environment rich in energy-dense foods, where food cues are omnipresent. In this context, hyperphagia driven by external food stimuli presents a unique challenge. While genetics certainly play a role in obesity, research suggests a complex gene-environment interaction.² This interaction may involve hedonic signaling, where environmental food cues and reward-predictive stimuli alter the brain’s reward circuitry.^3,4

Food-related environmental cues activate brain regions such as the striatum, orbitofrontal cortex, and amygdala — all of which are critical in reward processing. GLP-1 receptor agonists (GLP-1 RAs) disrupt these reward signals and help attenuate appetite. This makes them a promising treatment option for patients with obesity and/or diabetes who are driven to consume unnecessary calories due to hyperphagia. Recent research has shown that GLP-1 RAs are indeed a viable treatment for patients struggling with both hyperphagia and obesity, as well as those with diabetes.

How GLP-1s Treat Hyperphagia

Hyperphagia is not just a behavioral issue; it is also a neurological one, influenced by a food-rich environment and the associated food cues. GLP-1 receptor agonists (GLP-1s) work by suppressing appetite and enhancing satiety signals in the brain, with empirical evidence supporting their efficacy in treating hyperphagia.

 

Studies show that when patients with obesity or diabetes are treated with GLP-1 receptor agonists (GLP-1 RAs), there is a reduction in the activation of appetitive behaviors. This is particularly noticeable in brain areas such as the striatum, insula, and orbitofrontal cortex, especially when food-related visual cues are presented.⁵ One key mechanism by which GLP-1 RAs mitigate hyperphagia is by amplifying satiation signals. By mimicking the natural postprandial GLP-1 release, these medications promote earlier cessation of eating and help reduce portion sizes.⁴

Further evidence comes from PET scans, which show that reward-predictive cues — such as photographs of food — activate neural pathways and increase dopamine signaling.^4,6,7 Additionally, research using fMRI has demonstrated that merely viewing images of energy-dense foods activates the appetite-reward circuits in the brain. In fMRI studies that measured blood-oxygen-level dependent (BOLD) signals, liraglutide was shown to blunt the BOLD signal response in the insula, orbitofrontal cortex, and striatum when participants viewed images of energy-dense foods.⁴

Managing Hyperphagia with GLP-1 Medications and Comprehensive Treatment Plans

For patients exhibiting clinically clear signs of hyperphagia — such as chronic hunger, frequent snacking, and heightened food-cue reactivity — GLP-1 medications may offer significant relief. In individuals with hyperphagia, the signaling between the gut and brain is often dysregulated, and adding a GLP-1 receptor agonist (RA) to their treatment regimen can help manage this dysregulation while also promoting weight loss.

However, in addition to pharmacotherapy, a comprehensive treatment approach may be beneficial for these patients. Medically supervised diets that include clinical meal replacements, combined with a structured behavior change program, can further support weight management. These programs provide patients with nutritionally balanced, portion-controlled meal options, reducing the temptation of food cues and promoting more mindful eating habits. Coupled with behavioral strategies designed to address emotional or environmental triggers for overeating, such programs help patients develop healthier relationships with food and improve long-term adherence to weight loss plans.

 

Health care providers should consider discussing patients’ behavioral patterns and assessing whether hyperphagia-related symptoms are contributing to difficulties with weight loss. This is especially important for patients who, despite dietary changes, continue to struggle with excess weight. A combination of GLP-1 medication, medically supervised diets, and behavior change programs may offer the most holistic approach for managing hyperphagia and supporting sustainable weight loss.

Source(s):

1 Current and emerging therapies for managing hyperphagia and obesity in Prader-Willi syndrome: A narrative review

2 Evolutionary perspectives on the obesity epidemic: Adaptive, maladaptive, and neural viewpoints

3 Widespread reward-system activation in obese women in response to pictures of high-calorie foods

4 A role for GLP-1 in treating hyperphagia and obesity

5 GLP-1 receptor activation modulates appetite – and reward-related brain areas in humans

6 The timing of action determines reward prediction signals in identified midbrain dopamine neurons

7 Specialized coding of sensory, motor and cognitive variables in VTA dopamine neurons

 

About the Author: Dr. Dawn M. Sweet has over 20 years of experience in the field of communication. Dr. Sweet has given several invited talks to and workshops for academic and private sector audiences on the role of nonverbal and verbal communication in achieving positive outcomes and mitigating bias. Her research has been published in several top ranked peer-review journals, and it has been featured on NPR’s River to River / All Things Considered, Buzzfeed, and Science Daily. Her research has also been used to inform expert testimony.

About Robard: Robard Corporation has proudly set the standard for medical weight management since 1976. Our evidence-based weight management programs and science-driven nutritional products are the cornerstone of success for leading hospitals, physicians, and weight management clinics across the United States. To learn more about us and how we can help your practice and patients, visit us online www.Robard.com, email us at info@robard.com, or call (800) 222-9201.